How has been the historical performance of Sotac Pharma.?

Answer:The historical performance of Sotac Pharma shows a trend of increasing net sales and profitability over the years, with a notable rise in the latest fiscal year ending March 2025.

Breakdown:
Sotac Pharma's net sales increased from 28.60 Cr in March 2020 to 96.99 Cr in March 2025, despite a slight decline from 103.83 Cr in March 2024. The total operating income followed a similar pattern, reaching 96.99 Cr in March 2025. The company's operating profit (PBDIT) saw significant growth, rising from 1.86 Cr in March 2020 to 17.55 Cr in March 2025, with an operating profit margin of 14.07% in the latest year. Profit before tax also improved dramatically, from a loss of 2.06 Cr in March 2021 to a profit of 11.12 Cr in March 2025. Consequently, profit after tax increased from 0.09 Cr in March 2020 to 9.28 Cr in March 2025, reflecting a PAT margin of 9.57%. The company's total assets grew from 34.70 Cr in March 2021 to 123.03 Cr in March 2025, while total liabilities also increased, indicating a rise in debt from 17.13 Cr in March 2021 to 43.70 Cr in March 2025. Cash flow from operating activities remained negative in the latest year at -4.00 Cr, but financing activities provided a net inflow of 16.00 Cr. Overall, Sotac Pharma's financial trajectory indicates a strong recovery and growth in profitability and asset base over the past few years.